Aktienanalyse zu Quince Therapeutics Inc (QNCX)QNCXQuince Therapeutics Inc

IRulya Therapeutics, Inc., formerly Quince Therapeutics, Inc., is a clinical-stage biopharmaceutical company. It is developing a novel disease-modifying therapeutic to address the unmet medical need associated with pulmonary disorders. Its lead asset, LAM-001, a proprietary investigational inhaled dry powder formulation of rapamycin whose differentiated characteristics may permit treatment of pulmonary conditions associated with dysfunctional mammalian target of rapamycin activity. It is evaluating the use of LAM-001 as a treatment for patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and for patients with bronchiolitis obliterans syndrome post lung transplant (BOS). It also completed a Phase 2a trial, which enrolled patients with pulmonary arterial hypertension as well as patients with PH-ILD and sarcoidosis associated pulmonary hypertension (SAPH) where it achieved clinically relevant improvement across multiple endpoints, and others. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Quince Therapeutics Inc is a good buy right now due to its recent positive momentum and analyst support. The stock has seen a 5-day change of +8.66% and is currently trading at $31.73, with a consensus target price of $81.09 suggesting a potential upside of 168.96%. Additionally, the RSI is at 66.39, indicating strong momentum. However, the main risk is the company's recent financial performance, as it reported a net income loss of $75,488,000 in Q2 2026, which could impact investor sentiment if not addressed.